Phase i clinical trialto evaluate the pharmacokinetics, safety, and tolerability of one intramuscular injection of risperidone ISM® at different dose strengths in subjects with Schizophrenia or Schizoaffective disorder (PRISMA-1)

A clinical trial was conducted to characterize the pharmacokinetics and to evaluate the safety of Risperidone ISM® in subjects with schizophrenia or schizoaffective disorder (ClinicalTrials.gov identifier:

Saved in:
Bibliographic Details
Published inClinical therapeutics Vol. 37; no. 8; p. e47
Main Authors Llaudó, J., Ayani, I., Monreal, M., Martínez-González, J., Gutierro, I.
Format Journal Article
LanguageEnglish
Published Bridgewater Elsevier Inc 01.08.2015
Elsevier Limited
Subjects
Internal Medicine
Medical Education
Schizophrenia
Online AccessGet full text

Cover

More Information
Summary:A clinical trial was conducted to characterize the pharmacokinetics and to evaluate the safety of Risperidone ISM® in subjects with schizophrenia or schizoaffective disorder (ClinicalTrials.gov identifier:
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ISSN:0149-2918
1879-114X
DOI:10.1016/j.clinthera.2015.05.141